SP 0256
Alternative Names: hMPV mRNA LNP 1; Respiratory syncytial virus mRNA vaccine - Sanofi; RSV mRNA LNP 1; RSV mRNA LNP CL 0059; RSV mRNA LNP CL 0137; RSV mRNA LNP vaccine - Sanofi; RSV/hMPV mRNA LNP 1; RSV/hMPV mRNA LNP 2; RSV/hMPV mRNA Vaccine; SP-0256Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Sanofi
- Class Respiratory syncytial virus vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Metapneumovirus infections; Respiratory syncytial virus infections
Most Recent Events
- 18 Nov 2024 Sanofi plans to initiate a phase I/II trial for Metapneumovirus infections and Respiratory syncytial virus infections (Prevention) (IM) (NCT06686654)
- 11 Nov 2024 Phase-I/II clinical trials in Metapneumovirus infections (Prevention) in USA (IM) (NCT06686654)
- 11 Nov 2024 Sanofi initiates a phase I/II trial Respiratory syncytial virus infections (Prevention) (IM) in USA (NCT06686654)